As INPP4B expression is increased in PIK3CA-mutant ER+ breast cancers where it promotes cell proliferation and tumor growth [24], we questioned whether INPP4B also affects the sensitivity of ER+ breast cancer cells to standard-of-care therapies. This evidence concerns the gene ESR1 and neoplasm.